4.7 Article

Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells

Journal

CELL DEATH AND DIFFERENTIATION
Volume 21, Issue 2, Pages 258-269

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/cdd.2013.136

Keywords

cancer stem cell; DNA repair; glioma; radioresistance; PARP

Funding

  1. National Institutes of Health [CA154130, CA169117, CA1129958, CA151522]
  2. American Brain Tumor Association
  3. James S McDonnell Foundation
  4. Danish Council for Independent Research/Medical Sciences [ID4765/11-105457]
  5. Czech Ministry of Health [NT11065-5]
  6. European Commission [CZ. 1.07/2.3.00/20.0019, CZ. 1.05/2.1.00/ 01.0030]
  7. Danish National Research Foundation
  8. Novo Nordisk Foundation,
  9. Lundbeckfonden

Ask authors/readers for more resources

Glioblastoma-initiating cells (GICs) are self-renewing tumorigenic sub-populations, contributing to therapeutic resistance via decreased sensitivity to ionizing radiation (IR). GIC survival following IR is attributed to an augmented response to genotoxic stress. We now report that GICs are primed to handle additional stress due to basal activation of single-strand break repair (SSBR), the main DNA damage response pathway activated by reactive oxygen species (ROS), compared with non-GICs. ROS levels were higher in GICs and likely contributed to the oxidative base damage and single-strand DNA breaks found elevated in GICs. To tolerate constitutive DNA damage, GICs exhibited a reliance on the key SSBR mediator, poly-ADP-ribose polymerase (PARP), with decreased viability seen upon small molecule inhibition to PARP. PARP inhibition (PARPi) sensitized GICs to radiation and inhibited growth, self-renewal, and DNA damage repair. In vivo treatment with PARPi and radiotherapy attenuated radiation-induced enrichment of GICs and inhibited the central cancer stem cell phenotype of tumor initiation. These results indicate that elevated PARP activation within GICs permits exploitation of this dependence, potently augmenting therapeutic efficacy of IR against GICs. In addition, our results support further development of clinical trials with PARPi and radiation in glioblastoma.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available